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Executive Summary
Dengue/DHF  -  global public health burden
The geographical spread of both the mosquito vectors and the viruses has led to the
global resurgence of epidemic dengue fever/dengue haemorrhagic fever (dengue/DHF) in the
past 25 years with the development of hyperendemicity in many urban centres of the tropics.
Globally, 2.5 billion people live in areas where dengue viruses can be transmitted. The number
of countries with epidemic DHF is continuing to rise. A pandemic in 1998, in which 1.2 million
cases of dengue fever and DHF were reported from 56 countries, was unprecedented.  Data for
2001-2002 indicate a situation of comparable magnitude. It is estimated that 50 million dengue
infections occur each year with 500 000 cases of DHF and at least 12 000 deaths, mainly among
children. Only a small proportion of cases are reported to WHO. The challenge for national and
international health agencies is to reverse the trend of increased epidemic dengue activity and
increased incidence of DHF.
Rationale for global surveillance of dengue/DHF
Epidemiological and laboratory-based surveillance is required to monitor and guide
dengue/DHF prevention and control programmes, regardless of whether the form of control used
is mosquito control or possible vaccination if an effective and safe vaccine becomes available.
The reporting of dengue/DHF however is not standardized. Epidemiological and laboratory data
are often collected by different institutions and reported in different formats, resulting in delay
and comparability problems at regional and international levels. To address these problems
WHO has created DengueNet, an Internet-based central data management system to collect and
analyse standardized epidemiological and virological data for the global surveillance of
dengue/DHF and to provide national and international public health authorities with
epidemiological and virological indicators by place and time that can guide public health
prevention and control actions.
DengueNet WHO’s Internet-based system for global surveillance of dengue/DHF
The DengueNet system responds to the WHO resolution on dengue fever/DHF
prevention and control adopted at the 55th World Health Assembly in May 2002, asking Member
States “to build and strengthen the capacity of health systems for surveillance, prevention,
control and management of dengue and DHF” and emphasizing the critical importance of
strengthening laboratory diagnosis in affected countries. It is compatible with the principles
developed by PAHO for epidemiological and laboratory surveillance of dengue/DHF in the
Americas as outlined in the Resolution CD43.R4 and the Working Document CD43/12 adopted
by the PAHO Directive Council in September 2001.
At present, global dengue statistics from 1955 to 2001 can be accessed on DengueNet.
When fully implemented, public health authorities and the general public will have immediate
access to important indicators such as incidence data, case fatality rates (CFR) for DHF,
frequency and distribution of dengue and DHF cases, number of deaths, and distribution of
circulating dengue virus serotypes based on data that have been entered into the DengueNet
database via the Internet directly by national health officials. In addition, the historical and
current data contained in DengueNet will be useful for public health researchers to support their
research and for national and international agencies for advocacy purposes.
A key objective is to ensure that data of the highest possible quality is reported in a
timely manner to DengueNet. This can be achieved by implementing standards for surveillance,
laboratory procedures and quality control by establishing a strong
WHO/CDS/CSR/GAR/2003.8
PAHO/HCP/HCT/V/230/03
DengueNet Implementation in the Americas
Report of a WHO/PAHO/CDC meeting P erto Rico 9 11 J l 2002
2
partnership between the national programmes, WHO collaborating centres (WHO CC) and the
WHO country, regional and global levels.
DengueNet implementation
The first meeting on DengueNet implementation in the Americas was held jointly with
WHO/PAHO and the WHO collaborating centre for dengue at CDC on 9-11 July, 2002 in Puerto
Rico, USA.  The objective was to describe and demonstrate DengueNet  to prospective users and
launch pilot testing by building on the existing reporting systems and network of dengue
laboratories in the Americas.
Purpose and objective
Forty participants (surveillance epidemiologists and laboratory specialists) from 15
countries participated in this first meeting on implementation of DengueNet.  The focus of the
technical discussions in the plenary was (1) the challenge and need for global epidemiological
and laboratory surveillance of dengue and dengue haemorrhagic fever (DHF); (2) the national
epidemiology and laboratory surveillance systems in participating countries in the Americas; and
(3) presentation of DengueNet and a “hands-on” session with the Internet site.  Two working
groups were convened.  The first defined the epidemiological data and reporting requirements for
DengueNet, modifications needed to its present format, identification of countries for pilot
testing and the roles and responsibilities of national and international partners.  The second group
reviewed laboratory standards and quality control issues for dengue serological diagnosis and
virus isolation building on the recommendations of the two previous WHO meetings on dengue
laboratories in the Americas.
Meeting outcomes
This first meeting marks the start of the phased implementation of DengueNet starting
with the Americas in 2002 and expanding to the WHO South-East Asia and Western Pacific
Regions in 2003.  There was very active participation by representatives from national
programmes and laboratories, WHO collaborating centres and WHO/HQ, PAHO and country
offices.  The key outcomes are summarized below.
Data will only be provided by the central level of each country (one source of data per
country).  DengueNet will link to the country web pages for additional information.
Countries will provide this data by epidemiological week at state/department level for the
large countries and at the island level for island countries.  The data reported in DengueNet will
include the clinical categories of dengue fever, DHF, both suspected and confirmed cases, and
only confirmed dengue deaths.
Virus serotype data will be provided for the entire country as the number of isolations of
each serotype in the country.  DengueNet will display this data and the calculated proportion of
each serotype as a percentage of the sum of all four serotypes isolated  in the country for any
given time period.
Roles and responsibilities of the partners in this network
Countries will collect, validate, and provide epidemiological and laboratory data.  They
will designate the participating centres.  The WHO collaborating centres will continue to provide
technical laboratory support, reagents, proficiency panels and training to national laboratories.
PAHO will support the country implementation activities and WHO HQ will maintain and
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moderate the DengueNet web site. Both PAHO and WHO/HQ will seek financial support for
dengue surveillance activities.
Country participation
A major outcome of the meeting was that all the representatives of countries in the
Americas expressed interest in participating in DengueNet pilot test, and the representatives of
South-East Asian countries indicated interest in having the system expanded to include their
region.  The participants will follow up with their country authorities to obtain official
authorization to participate in DengueNet.  WHO Country representatives will support the
participants in presenting the DengueNet proposal to the country authorities.  The pilot testing
of DengueNet in the Americas will be conducted over a 3-6 month period.  The lessons learned
will be built into the implementation framework for high-burden countries in the South-East
Asian and Western Pacific Regions in 2003.
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1. Introduction
This meeting on DengueNet implementation in the Americas was organized by the World
Health Organization Department of Communicable Disease Surveillance and Response, Global
Alert and Response, (WHO/CSR/GAR) jointly with the Pan American Health Organization
Division of Communicable Disease Prevention and Control (PAHO/HCP/HCT) and the WHO
Collaborating Centre (WHO CC) for Dengue Reference and Research at the Dengue Branch,
Division of Vector-Borne Infectious Disease (DVBID), US Centers for Disease Control and
Prevention (CDC) in Puerto Rico.
1.1 Welcome
Dr Gary Clark welcomed the participants at the WHO CC in Puerto Rico and gave a brief
description of the Dengue Branch/CDC facilities and programme and the WHO CC activities
related to national programme support, provision of laboratory training, reagents, quality control
and reference services, and assistance to countries during epidemics.
1.2 Meeting objectives and expected outcomes
Dr Ray Arthur outlined the meeting objectives and expected outcomes.  The meeting was
convened to:
 Present DengueNet, WHO's  global surveillance system for dengue/DHF, to
prospective users and allow participants to have “hands-on” experience with the
Internet site;
 Identify modifications and specific tasks that are required before
implementation/pilot testing of DengueNet;
 Review the national systems for dengue/DHF surveillance in the Americas as these
relate to implementation of DengueNet; including epidemiological surveillance and
reporting systems, laboratory diagnosis and virus characterization, communication
and information flow;
 Review and update the recommendations of the two previous WHO meetings for
dengue laboratories in the Americas relative to diagnostic testing, laboratory
standards and quality control for serology, PCR, virus isolation, serotyping and
characterization;
 Identify countries for DengueNet pilot testing and the respective roles and
responsibilities of countries, WHO Collaborating Centres, WHO country offices,
PAHO and HQ.
The overall objective was to develop a framework for the implementation of DengueNet
with emphasis on data quality and active participation of national programmes and to launch
pilot testing in the Americas by building on the existing reporting systems and networks of
dengue laboratories.
The expected outcomes of the meeting are:
 Recommendations for modifications to be made to the present version of DengueNet;
 Definition of epidemiological and laboratory data and reporting requirements for
DengueNet;
 Identification of potential participation of countries and time frame for the pilot
testing;
 Definition of the roles and responsibilities of national and international partners.
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1.3 Participants, agenda and documents
The meeting chairman was Dr Robert Shope and Dr Scott Halstead was rapporteur. Forty
participants from 15 countries included surveillance epidemiologists and laboratory specialists
from:
 National programmes of high-burden countries in the Americas: Brazil, El Salvador,
French Guyana, Guatemala, Nicaragua, Mexico, Puerto Rico, Venezuela;
 CAREC, WHO's sub-regional surveillance network for twenty island countries in the
Americas, located in Trinidad;
 WHO Collaborating Centres for dengue, arbovirus and viral haemorrhagic fevers
located in Argentina, Brazil, Canada, Cuba and the United States of America;
 Indonesia, Thailand, and Viet Nam - these 3 participants attended the meeting to
benefit from the discussions and to assist WHO in organizing a DengueNet
implementation meeting in 2003 for high burden countries in South-East Asia and
the Western Pacific;
 WHO HQ, PAHO and Country offices in Brazil and Nicaragua.
The agenda, list of participants and background documents are presented in Annexes 1, 2
and 3 respectively.
1.4 The challenge of dengue/DHF epidemiological and laboratory surveillance
Dr Duane Gubler gave an overview of the challenges in dengue/DHF epidemiological
and laboratory surveillance.
The geographic spread of both the mosquito vectors and the viruses has led to the global
resurgence of epidemic dengue fever/dengue haemorrhagic fever (dengue/DHF) in the past 25
years with the development of hyperendemicity in most urban centres of the tropics and
emergence of epidemic DHF in these areas.  The challenge for national and international health
agencies is to reverse the trend of increased epidemic dengue activity and increased incidence of
DHF.
Surveillance is an important component of a dengue/DHF prevention programme.
Unfortunately, surveillance for these clinical syndromes is not effective in most endemic
countries.  Generally, only passive surveillance systems are used, and only severe disease is
reported leading to a gross under-reporting of dengue illness.  In addition, even though WHO has
had a standardized case definition for DHF for many years, many countries do not use it for
reporting purposes. The result is that we do not know how much dengue illness actually occurs in
the world.
There are several principal challenges to implementing effective surveillance for
dengue/DHF.  The first and perhaps most important is to obtain the funding to develop and
support surveillance in all dengue endemic countries.  To achieve this, it is important to educate
policy-makers and institutional funding agencies about the extent of the public health and
economic problems associated with epidemic dengue/DHF.  Adequate resources and support will
only come after dengue/DHF is elevated to a higher priority as a public health problem.
Another challenge will be to implement both passive and active surveillance in endemic
countries.  Passive surveillance systems should be mandated by law and should report both
dengue fever and DHF using standard WHO case definitions.  Active surveillance should be
laboratory-based and have both virologic and serologic support, at least at the national level.
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Case reports should be transmitted electronically from the local to the state/provincial
level to the national level, and from there to WHO for international use.  The DengueNet system
could be ideal for this type of reporting.  Emphasis should be placed on the inter-epidemic period
using an active surveillance system, and should focus on monitoring dengue virus transmission
in the catchment area in order to know at any point in time, where dengue transmission is
occurring, what serotypes are involved, and what type of illness is associated with the virus
serotypes present.
Dengue vaccine development has made excellent progress in recent years.  Active,
laboratory- and population-based surveillance will be required in selected sites to monitor
vaccine efficacy trials.  In summary, effective, laboratory-based surveillance will be required to
monitor and guide dengue/DHF prevention programmes, regardless of whether the form of
control is mosquito control or vaccination.
2. Proceedings - Outline of meeting sessions
Five sessions were conducted during the meeting.  Sessions 1-3 were organized as
plenary sessions with presentations followed by a discussion led by a moderator.
On the first day, the meeting was held at the CDC dengue branch in San Juan.  Two
plenary sessions were conducted: the first on national systems for surveillance of dengue/DHF in
the Americas moderated by Dr Jorge Arias and the second on DengueNet for global surveillance
moderated by Dr Ray Arthur.  Eleven computers connected to the Internet were made available
to participants in groups of 4 for a hands-on experience with the DengueNet Internet site before
the second session opened  for discussion.  The day ended with a visit of the centre's
epidemiology, laboratory and entomology facilities.
Day 2 included the third plenary session during which (1) Dr Ray Arthur summarized the
day 1 discussions on DengueNet for the benefit of participants who joined the meeting on day 2
and (2) Dr Gary Clark presented a review of the recommendations of the 1994 and 1996 WHO
meetings on dengue laboratories in the Americas.  During the fourth session the meeting
participants  divided into two working groups one on epidemiology and the second on laboratory
issues for dengue/DHF surveillance as these relate to DengueNet.
Session 5 on day 3 was a plenary session and included reports from the two working
groups followed by discussions and presenting consensus on the meeting recommendations. The
first defined the epidemiological data and reporting requirements for DengueNet, modifications
needed to its present format, identification of countries for pilot testing and the roles and
responsibilities of national and international partners.  The second group reviewed laboratory
standards and quality control issues for dengue serological diagnosis and virus isolation building
on the recommendations of the two previous WHO meetings on dengue laboratories in the
Americas.
2.1 Session 1: National laboratories and reporting systems for dengue/DHF in the Americas
Moderators: Dr Francisco Pinheiro and Dr Jorge Arias
This session reviewed selected national systems for epidemiological and laboratory
surveillance of dengue/DHF in the Americas in relationship to the proposed implementation of
DengueNet and identified topics requiring further discussion to define the data on dengue/DHF
cases and deaths and on circulating dengue virus that will be reported to DengueNet.
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2.1.1 Questionnaire survey of national dengue/DHF laboratories & reporting systems
Prior to the meeting, WHO developed a comprehensive questionnaire for dengue/DHF
surveillance and reporting systems and dengue laboratories.  Dr Jorge Arias from PAHO
conducted the questionnaire survey for countries and collaborating centres in the Americas
participating in this meeting.  Preliminary results of the survey were presented at the meeting
based on an analysis of the completed questionnaires received from 7 national programmes, and
8 collaborating centres including CAREC in the Americas.  They show that dengue testing is
mandatory in 8 countries, DHF notification is mandatory in 7 countries and the frequency of
dengue reporting during epidemics is daily.  Most collaborating centres and country health
ministries maintain a website.  All countries are in regular communication with PAHO, but
require authorization to share epidemiological data.  Reports are sent electronically, by fax, post
and telephone from the periphery to national level and from there to the regional/  international
level. All countries are willing to participate in DengueNet.  All collaborating centres and most
countries are able to isolate and identify dengue viruses.  Six centres and 2 countries have the
capability to produce dengue antigens and provide them for other users.  Four countries
participate in a quality control programme.  The number of regional laboratories in member
countries varies from 1 to 33.
2.1.2 Dengue/DHF lab based surveillance DHF system in Puerto Rico
Dengue surveillance in Puerto Rico is a laboratory-based, population-based surveillance
system, with close co-ordination between the epidemiology and laboratory components and the
Puerto Rico Department of Health (PRDH) and the US Centers for Disease Control and
Prevention (CDC) respectively.  A reported case is defined as any person whose illness is
considered compatible with dengue by a health care professional in Puerto Rico, and whose
diagnostic sample is sent to the CDC Dengue Branch for testing.  WHO/PAHO case definition is
used for DHF.  The routine laboratory methods are virus isolation, IgM and IgG (ELISA) tests,
and immunohistochemistry for antigen detection in autopsy samples.  The predictive value that a
reported case is dengue is at least 75%.
The objective is to provide early and precise information on when and where
transmission is occurring, the serotypes present, the associated disease severity, and guide
clinical and vector control interventions.  Key attributes of the surveillance system include
simplicity, acceptability, flexibility and high coverage.  Timeliness is constrained by the
characteristics of disease transmission and diagnostic methods.
2.1.3 Dengue fever in Brazil: Past, present and perspectives
In Brazil 70% of the population corresponding to l 174 million people live in the north-
east and the south-east regions where the majority of dengue cases occur.  Brazil has experienced
its largest epidemic ever in the first four months of 2002 with 560 000 cases reported to date
(preliminary data), and 53% of these occurring in the state of Rio de Janeiro.
This epidemic has been caused by the recent introduction of the dengue 3 serotype that
was first detected in the state of Rio de Janeiro in 2000.
Dengue 1 serotype was first detected in Rio de Janeiro state in 1986 and dengue 2
serotype in 1990.  Dengue incidence increased during the 90's and in 1998, Brazil reported over
530 000 cases.  Following the current major epidemic this year, a national programme for dengue
prevention and control has been developed with stringent objectives to reduce dengue incidence
and Aedes aegypti indices, to prevent dengue outbreaks and to reduce the case fatality rate for
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DHF.  Key components of this programme include improved case and laboratory based
surveillance, integration of these with vector control activities, continuous
training of field staff and of health care personnel for case management of DHF, integrated
health education and community participation and improved legislation.
2.1.4 Dengue/DHF surveillance in CAREC - regional surveillance network
The PAHO/WHO Caribbean Epidemiology Centre (CAREC) provides epidemiology and
laboratory reference services to 21 member countries in the Caribbean ranging from 4 000 to 2.5
million people per country and for a total population of 7.2 million people.  CARISURV the
surveillance system for the collection, analysis, interpretation, reporting and dissemination of
Caribbean public health information has 12 components.  Dengue surveillance is based on three
components : EPISUM (the communicable disease database), LABIS (the laboratory information
system) and PHLIS (the public health laboratory information system).  The larger CAREC
member countries have three reporting levels for communicable diseases, and in the smaller
countries, the functions of level 2 are split between levels 1 and 3.  All member countries use the
same case definitions for dengue fever, dengue haemorrhagic fever (DHF) and dengue shock
syndrome (DSS).  Laboratory methods used are IgM ELISA, dengue virus isolation and PCR,
and haemagluttination inhibition (HI).  The objectives of laboratory surveillance are to identify
new serotypes, identify spread of the epidemic into new areas and to monitor severe, complicated
and fatal cases attributed to dengue fever.  During epidemics, a limited number of probable cases
are tested and laboratory confirmations of new dengue serotypes are reported immediately.
2.1.5 Characteristics of national dengue/DHF surveillance programmes
Four countries  (El Salvador, Mexico, Nicaragua, Venezuela) presented their national
programmes with a focus on the surveillance objectives, data collected, information flow and
epi-lab coordination, weaknesses and challenges.  Key points in the description of characteristics
are summarized below:
 The principal objective of the national surveillance programmes in the four countries
is to provide quality and timely information to decision-makers to facilitate disease
prevention and control activities.
 The four countries collect data/information on different types of dengue cases (such
as dengue fever, dengue haemorrhagic fever, hospitalizations, deaths, laboratory-
positive cases) through different and parallel systems, usually weekly, but daily
during epidemics.
 Regarding the information flow, the epidemiological and laboratory data collected by
the several systems used in each country usually comes together at the epidemiology
office at the central level that coordinates the data collection, analysis and feedback.
All countries post the surveillance data on a website.
 Although one country indicated that the principal challenges in its system were to
speed the movement and improve the quality of information, most countries
indicated that the lack of human and material resources was the principal obstacle for
surveillance.
2.1.6 Discussion
The discussion points concerning the participation of national programmes in DengueNet
and the standards for reporting case-based and virological data to this global dengue/DHF
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2.2 Session 2: DengueNet for global surveillance of dengue and DHF
Moderator: Dr Ray Arthur
2.2.1 Why global surveillance for dengue and DHF?
Globally 2.5 billion people now live in over 100 countries/territories where dengue
viruses can be transmitted.  The rapid spread of viruses through travel and trade has led to the
global resurgence of epidemic dengue fever//DHF) in the Americas, South-East Asia, the Eastern
Mediterranean and the Western Pacific.
The public health burden is due to the increase in both incidence and severity of
dengue/DHF.  Before 1970, only nine countries had experienced epidemic DHF.  Now, the
number has increased more than fourfold and continues to rise.  A pandemic in 1998, in which
1.2 million cases of dengue fever and DHF were reported from 56 countries, was unprecedented.
Data for 2001-2002 indicate a situation of comparable magnitude.
It is estimated that 50 million dengue infections occur each year with 500 000 cases of
DHF and at least 12 000 deaths, mainly among children.  Only a small proportion of cases are
reported to WHO.  The challenge for national and international health agencies is to reverse the
trend of increased epidemic dengue activity and increased incidence of DHF.
Epidemiological and laboratory-based surveillance is required to monitor and guide
dengue/DHF prevention and control programmes, regardless of whether the form of control used
is mosquito control or possible vaccination if an effective and safe vaccine becomes available.
The surveillance system should monitor dengue virus to show at any point in time, where dengue
transmission is occurring, what serotypes are involved, and what type of illness is associated
with the virus serotypes present.
Case reports should be transmitted from the local to the state/provincial to the national
level and from there to WHO for international reporting and use.  The reporting of dengue/DHF
however is not standardized.  Epidemiological and laboratory data are often collected by
different institutions and reported in different formats, resulting in delay and comparability
problems at regional and international levels.  To address these problems and the rising disease
burden,WHO has created DengueNet , an Internet-based central data management to:
 Collect and analyse standardized epidemiological and virological data in a timely
manner and present epidemiological trends, as soon as new data are entered; and
 Display in real-time important indicators such as incidence data, case fatality rates
(CFR) for DHF,  frequency and distribution of dengue and DHF cases, number of
deaths, and distribution of circulating dengue virus serotypes.
DengueNet will provide national and international public health authorities with
epidemiological and virological information by place and time that can guide public health
prevention and control actions.  Being able to monitor virus transmission and circulating
serotypes by place and time in the inter-epidemic periods will be useful for an early warning of
dengue activity in neighboring states and countries to plan dengue prevention or control
strategies; this is particularly important in the American region characterized by unstable dengue
epidemic activity with emerging DHF cases.
The system also provides information on CFR by place and time and this can be used
effectively to target training to countries and regions that need to improve the hospital-based
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DHF case management to reduce CFR; this is particularly important in South-East Asia, where
all four dengue viruses are endemic and DHF cases occur year after year and CFR are used to
monitor progress in hospital case management and public education campaigns.
In addition, DengueNet contains valuable historical and current data that may be useful
for public health researchers to support their research and that could be used by national and
international agencies for advocacy purposes.




The DengueNet system is compatible with the PAHO strategy and guidelines for
epidemiological and laboratory surveillance of dengue/DHF in the Americas as described in the
PAHO Resolution CD43.R4 and Working Document CD43/12 adopted by the Directive Council
in September 2001.
2.2.3 WHO Resolution WHA55.17 for dengue fever/DHF prevention and control
http://www.who.int/gb/EB_WHA/PDF/WHA55/ewha5517.pdf
DengueNet is directly responsive to the resolution adopted at the 55th World Health
Assembly in May 2002, asking Member States “to build and strengthen the capacity of health
systems for surveillance, prevention, control and management of DF and DHF” and emphasizing
the critical importance of strengthening laboratory diagnosis in affected countries.
2.2.4 DengueNet WHO’s web-based global surveillance system for dengue/DHF
http://www.who.int/wer/pdf/2002/wer7736.pdf
DengueNet has been developed in collaboration with the WHO Collaborating Centre for
Electronic Disease Surveillance for Public Health at the INSERM in France with seed financial
support from NASA and TDR and based on the previously developed FluNet for global
surveillance of influenza, also a collaborative development with this centre.
The main features of this Internet-based global surveillance system are:
 User friendly password-protected remote one standard data input by all DengueNet
partners worldwide, with data updated on a real-time basis;
 Inclusion of the state/province subdivisions of the countries for which data will be
entered and indicators such as incidence calculated;
 Dynamic query facility with analysis and presentation real-time information about
epidemic activity and circulating serotypes in graphic, tabular, map and free-text
formats ;
 Use of GIS tools to provide real-time map of the epidemiologial situation;
 Links to the dengue web pages of WHO offices, countries, collaborating centres,
research and medical institutions working worldwide on dengue/DHF prevention and
control;
 An up-to-date directory of national and international partners in the DengueNet
network;
 Dengue news, information and document centre
 Available information accessible in the public domain.
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At present, global dengue statistics from 1955 to 2001 can be accessed on DengueNet.
As countries begin entering data into DengueNet, real-time updates of standardized
epidemiological and virological data will become available.  When DengueNet is fully
implemented, public health authorities and the general public will have immediate access to
epidemiological data on dengue, DHF cases and deaths based on standardized case definitions,
and virological data on the circulating dengue virus serotypes, Den 1, 2, 3 and 4 that have been
entered into the DengueNet database via the Internet directly by national health officials.
A key objective is to ensure that data of the highest possible quality is reported in a
timely manner to DengueNet.  This may be achieved by standards for surveillance, laboratory
procedures and quality control that are supported by a strong partnership between the network
partners involved including the national programmes, WHO collaborating centres and WHO
country, regional and global levels.
2.2.5 Practical “hands-on” session with DengueNet
www.who.int/denguenet
A practical "hands-on" session with DengueNet was conducted and participants in groups
of 2 to 4 were able to query DengueNet on the official data reported to WHO from 1955 to date
from countries worldwide.  They also reviewed the restricted data entry site in DengueNet.
2.2.6 Discussion
The discussions centred on the DengueNet website, the modifications and further
developments needed, the target audience and the added value that this site provides.  The roles
and responsibilities of the users and providers were also discussed.  Key points from discussions
are included in the recommendations of the epidemiology working group.
2.3 Session 3: 1994 and 1996 WHO meetings on dengue labs in the Americas
Moderator: Dr  Francisco Pinheiro
2.3.1 Summary of day 1
Dr Ray Arthur presented a summary of day 1 for the benefit of participants who joined the
meeting on day 2.
2.3.2 1994 Cincinnati Meeting on diagnostic methods and commercial assays
Representatives from laboratories in Europe, Asia, Africa and the Americas met to
review the diagnostic methods used and the commercial tests available for dengue diagnosis.
Discussion centered on the ways to standardize and improve these techniques and on creating
panels of well characterized sera for evaluating/validating new tests and commercial assays.
Research priorities for WHO CCs included development of accurate and inexpensive rapid tests,
evaluation of expression products as possible antigens in diagnostic tests and development of
dengue serotype-specific serological assays.  Expanding proficiency testing to include all dengue
laboratories in the Americas was recommended and considered an important role of the WHO
CCs (meeting report available).
2.3.3 1996 Rio de Janeiro Meeting on dengue laboratories in the Americas
At this meeting,  an ad hoc committee of 12 dengue virologists  met to review the
capability and capacity in dengue laboratories in the Americas.  A laboratory survey, including a
PCR survey, was conducted in 16 countries in the Americas by PAHO, to focus on developing
strategies to ensure the availability and quality of diagnostic reagents, validation of kits,
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improving laboratory quality control, training and communications. Detailed recommendations
that were developed on these issues are available in the meeting report. Recommendations
include establishing of laboratory and surveillance networks, training, communications, reporting
and feedback (meeting report available).
The preliminary survey of national laboratories, surveillance and reporting programmes
conducted for this meeting showed that all countries have serological and virological testing
capabilities but more attention needs to be given to availability of reagents, laboratory standards,
continuity in service training and quality control programmes.
2.4 Session 4: Working groups on dengue epidemiology and laboratory
The participants, epidemiologists and laboratory specialists, divided into two working
groups, one on dengue epidemiology and the other on laboratory, that convened for this session
on day 2.
2.4.1 Working group on dengue laboratories
The laboratory working group included representatives from the following countries or
jurisdictions in the Americas: CAREC, El Salvador, Guatemala, Mexico, Nicaragua, and
Venezuela.  Puerto Rico was represented by CDC Dengue Branch staff.  The 6 collaborating
centres were also represented.  Two participants had also participated in the 1994 Cincinnati and
the 1996 Rio de Janeiro WHO meetings on dengue laboratories in the Americas. The moderators
were Dr Francisco Pinheiro and Dr Vance Vordam.  The rapporteurs were Dr Delia Enria, Dr
Luiza de Souza and Dr Rosa Alba Salas.  The task of the laboratory group was to review the
laboratory standards and quality control issues for dengue serological diagnosis and virus
isolation building on the recommendations of the two previous WHO meetings on dengue
laboratories in the Americas.
2.4.2 Working group on dengue epidemiology
The epidemiology working group included representatives from the following countries
or jurisdictions in the Americas: French Territories, Brazil, El Salvador, Guatemala, Mexico,
Nicaragua, and Venezuela.  Puerto Rico was represented by CDC Dengue Branch staff.  The
three participants from Indonesia, Thailand, and Viet Nam also attended.  The moderator was Dr
José Rigau.  The rapporteurs were Dr João Bosco Siqueira and Dr Enid Garcia.  The task of the
epidemiology group was to define the epidemiological data and reporting requirements for
DengueNet, modifications needed to its present format, identification of countries for pilot
testing and the roles and responsibilities of national and international partners.
2.5 Session 5: Reports on working groups on dengue epidemiology and laboratory
Moderator: Chairman and Dr Ray Arthur
The working groups presented their reports in a plenary session on day 3 followed by
discussion and consensus on the recommendations and action points of each group.
2.5.1 Report of the working group on dengue laboratories
The meeting recommendations and action points for the laboratory topics considered,
included an update of the1994 and 1996 meetings recommendations for these topics.
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Reagents
a. Collaborating Centers (CCs) at CDC, UTMB, IEC, IPK will continue to support
national laboratories capable of producing reagents such as antigens.  This support
includes technical assistance activities such as provision of protocols, seed virus, cell
lines, consultation and training at CCs or at national laboratories.  These activities
will continue to be funded as previously by PAHO and WHO country offices.
b. PAHO should provide funds to CCs for reagent production, but national laboratories
are encouraged to become self sufficient in supplies.  For non antigen-producing labs
use of kits is an option.
c. CDC will continue to do research on recombinant antigen to alleviate this problem.
d. CDC will continue to provide conjugate and monoclonal antibodies (and hybridoma
cell lines to labs that have capacity for local production of MAbs) for ELISA and FA
tests.
Quality control of antigen produced at country level
a. CCs will provide small amounts of standard reference antigen to the national labs for
calibrating their locally produced reagent.
b. Every lab/country producing antigen is encouraged to send a vial from each batch
produced to any of the CCs at CDC, IEC, IPK, and UTMB for quality control.
Proficiency tests
a. The CCs at CDC, IPK will continue to make proficiency tests for serology available.
Feedback on results and recommended actions will be provided to individual
laboratories.  Results will guide PAHO in directing training and other support
activities.
b. Participation in proficiency tests will be required to participate in DengueNet.
c. National laboratories are encouraged to request a test at least once a year.
d. National reference laboratories are encouraged to maintain in-country proficiency
tests on a continuing basis.  Consultations and technical assistance for establishing
proficiency test procedures and panels can be obtained from the CCs.  Proficiency
tests for serology should be composed of at least 33% negatives, and the remainder
of low to intermediate positives.  Samples of various specificities should be included
if available.
e. Proficiency tests for virus isolation/identification and PCR should be attempted
within constraints of shipping regulations.  CDC can import virus isolates for
confirmation, however, exportation of live virus to collaborating countries is more
difficult and time consuming.
Commercial kits
a. Diagnostic kits should be evaluated before they are used in national programmes.
Mid-level evaluations (+200 samples) of kits, as they become known, will be
performed at the CCs at CDC/Puerto Rico and UTMB/Texas and possibly also at the
CCs at IPK/Cuba, IEC/Brazil and the National Microbiology Laboratory/Canada.
Summaries of results will be available on request.
b. National and local laboratories are encouraged to perform low-level evaluations (+20
samples) to ensure that individual lots of kits are functional and that lab personnel is
performing the test properly.
c. Attempts should be made to coordinate kit evaluations with WHO/TDR.
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Training
PAHO should continue to support training in laboratory diagnostic techniques at the CCs
and on site visits to the laboratories.
PCR
It is strongly recommended that laboratories using PCR for primary testing confirm
positive results by cell culture isolation if possible, serologically, or by an independent set of
primers before results are reported.
Detection of other flaviviruses and specific serologic diagnosis
a. Surveillance for YF, SLE, WN and other flaviviruses should be incorporated into
dengue diagnostic protocols.  These would include isolates positive with flavivirus
group-reactive reagents, and negative in dengue-specific tests.  Laboratories using
PCR as screening tests should include flavivirus universal primers along with type-
specific primer sets.
b. In anticipation of dengue vaccine trials and/or the appearance of new flaviviruses in
an area, national laboratories are encouraged to acquire competence in the type-
specific plaque reduction neutralization test (PRNT) for differential diagnosis.  For
those countries that have tissue culture capability, CDC can provide individual
training in the PRNT.
c. In this regard, the evaluation of the specificity of serologic tests and antigen cross
reactivity within the flavivirus genus was recommended.
d. Research programmes for the evaluation of the immune response in secondary
flavivirus infections are encouraged.
Information exchange
It is recommended that countries should maximize coordination and electronic
information exchange from laboratory to epidemiology sections in order to enable timely data
entry into DengueNet.
Laboratory function
The primary function of national central laboratories should be disease surveillance rather
than offering a diagnostic service.  Accordingly, agreements should be made with public health
authorities in advance that:
 the flow of samples from febrile patients during inter-epidemic periods should be
maintained; and
 the laboratory will selectively test the highest priority samples during epidemic
periods.  High priority samples include fatal cases, DHF cases, hospitalized cases,
and samples from areas not yet experiencing epidemic transmission.
Laboratory manual
Efforts will be made to arrive at a manual of standard laboratory procedures for
virological and serological diagnosis of dengue virus infections as a reference for global use.
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2.5.2 Report of the working group on epidemiology
The focus of recommendations and action points was on all topics that need to be
considered for DengueNet pilot testing.
Country participation
All the representatives of countries in the Americas expressed interest in participating in
the DengueNet pilot test, and the representatives of South-East Asian countries indicated interest
in having the system expanded to include their region.
The representatives of countries in the Americas discussed the steps they would pursue to
present DengueNet to country authorities, including national dengue committees and ministers of
health.  A two-month period (August - October, 2002) was considered adequate to obtain official
authorization for the country’s participation in the pilot programme.
It is expected that PAHO representatives in each country will support the meeting
participants in presenting the DengueNet proposal, and that countries will send to WHO the
electronic maps of their states or departments (with population data).
Additional time may be necessary before the start of the pilot testing with data entry, if
there is need for installing any software or training personnel.
Pilot programme
Given the seasonal nature of dengue and the need to have sufficient time for periodic data
entry, feedback to countries and to WHO, and additional time to test corrections or refinements,
it was suggested that the pilot programme should last from three to six months, depending on the
system’s performance.  Participants proposed the period from November 2002 to April 2003 and
the following timeline:
Year 2002 2003
Month 8 9 10 11 12 1 2 3 4 5 6 7
Obtain approval from countries’
Ministries of Health
X X X X
Pilot programme- Data entry X X X X X X
Pilot programme- Feedback from
and to countries
X X X X X X X X
Pilot programme- Evaluation X X X X X
Data collection
The discussion of the data to be included in DengueNet was organized around the
principal epidemiologic variables of time, place, and personal characteristics, with the addition of
information about the virus.
Time
Six of the eight participants from the Americas produce reports of suspected cases by
week of report of case, while Brazil produces weekly reports of suspected cases by week of onset
of illness, and Nicaragua produces reports of confirmed cases by week of onset of illness.
It was therefore decided that information should be entered by epidemiological week of report of
case, but two countries, Brazil and Nicaragua, will provide data by week of onset.
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Place
Countries will provide data at state/department level (depending on the country’s
terminology), except for the Caribbean island countries that will provide island-wide data only.
Personal characteristics
a. Only three countries routinely collect data on whether the case is hospitalized.
b. Six countries collect case age data by age group, and unfortunately the groupings are
not identical, therefore participants agreed that information on sex and age could not
be provided at this stage.  Nevertheless, the information is available on each
country’s health website, and DengueNet should inform users to use the link to each
country’s website.
c. The clinical categories to be reported are dengue fever (DF), dengue hemorrhagic
fever (DHF) and fatalities.  Participants were encouraged to report both suspected
and confirmed cases, as recommended by the Resolution CD43.R4 adopted in
September 2001.
d. All participating countries in the Americas adhere to the WHO / PAHO clinical case
definitions, but the usage is as follows:
   In most countries, although there is a DF case definition, DF cases are not
reported with specific symptoms and signs, so it is not possible to verify the
clinical diagnosis.
   In contrast, in most countries all reported cases of DHF are investigated, and the
clinical signs, symptoms, and hospital records (if any) are reviewed to determine
if the criteria for DHF are fulfilled.
e. For most countries, confirmation of cases requires a positive laboratory diagnosis of
dengue, but cases with only a single positive anti-dengue IgM antibody
determination are also considered confirmed (according to the WHO / PAHO
laboratory case definitions, such cases would only be classified as probable).
Two countries, Guatemala and Venezuela will classify a case as confirmed in the
absence of a positive laboratory diagnosis of dengue, but only after a committee
composed of epidemiologists and clinicians evaluates all data on the case and
considers that the clinical illness is compatible with dengue.
f. Countries will report only confirmed fatalities in DengueNet, meaning only
laboratory confirmed cases, except for Guatemala and Venezuela who also confirm
fatalities by clinical criteria.
g. The calculation of case fatality rate (CFR) was discussed, and the group
recommended that DengueNet calculate CFR using confirmed deaths as numerator
and confirmed DHF cases as the denominator:  CFR = Confirmed Deaths /
Confirmed cases of DHF
Virus serotype
a. This information will be provided for the entire country as it is available, not
necessarily every week, and it will be entered in a separate box (see Sample Form
below), which will include the number of isolations of each serotype in the country
for a given time period.
b. It was requested that the DengueNet screen be programmed to calculate the
percentage that each virus represents among all virus isolations, and that the screen
also shows the date of last update.
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General considerations
All participants agreed on the following points:
a. Data will only be provided by the central level of each country (one source of data
per country).
b. Data should be provided weekly, if possible, but it is recognized that during epidemic
periods may require different routines
c. Indications of alert or epidemic situations should only be defined or posted by the
respective country, and not by the DengueNet system itself.
d. Additional data will be provided in the countries’ web pages, and a link should be
made in DengueNet.
e. Several general notes must be displayed in DengueNet during the pilot testing:
   The DengueNet screen must always show a disclaimer indicating that “2002-
2003 data are not official country information,” or “2002-2003 data are
provisional - System being tested.”
   It was recognized that the data are public (and most countries display it on their
own Health websites), but that the DengueNet system being in construction, may
show data incorrectly for a brief period if any programming error occurs.
   There should be an indication that countries apply the WHO/ PAHO clinical
definitions, and the specification of what “confirmed” means regarding
laboratory diagnosis of cases and the classification of cases and fatalities (as
noted for specific countries above).
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Sample DengueNet Data Entry Form
Epidemiologic week: ___
Epidemiologial activity  (optional)
State     Dengue Cases       DHF  Cases     Deaths
/ Dept           Probable   Confirmed Probable   Confirmed             Confirmed
Note:  WHO/PAHO definitions in Annex 5.
Country report (optional)






Display the distribution of each serotype as % of the sum of all four serotypes.
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Annex 1: Agenda
Meeting on DengueNet Implementation in the Americas
Follow up of 1996 Rio de Janeiro and 1994 Cincinnati meetings of dengue laboratories
San Juan, Puerto Rico  9 – 11 July 2002
Venue:  Tuesday 9 July, Centers for Disease Prevention and Control,
Division of Vector Borne Infectious Diseases, Dengue Branch
Time Tuesday 9 July 2002       Presenter/Moderator
8:30 - 8:45 Welcome & introduction of Gary Clark
participants, chairperson and rapporteur
8:45 - 9:00 Objectives, expected outcomes Ray Arthur
process of meeting, background papers
9:00 - 9:30 The challenge of dengue/DHF epidemiological  Duane Gublerand laboratory surveillance
Session 1
9:30 - 10:00
National labratories and reporting systems Moderator: José Rigau
for dengue/DHF
Questionnaire survey – objectives, analysis and results Jorge Arias





CDC-PR laboratory based surveillance programme José Rigau
Dengue fever in Brazil – past, present and perspectives João B. Siqueira
CAREC sub-regional network Rosa Alba Salas
Characteristics of national programmes in the Americas 
El Salvador, Mexico, Nicaragua, Venezuela        Romeo Humberto Montoya
 Objectives of surveillance Luis Anaya Lopez
 Data collected - reporting and feedback Wendy Idiáquez




12:30 – 13:30 LUNCH
Session 2
13:30 - 14:00
DengueNet global surveillance network Moderator: Ray Arthur 
for dengue/DHF
Why global surveillance for dengue/DHF Ray Arthur
14:00 - 14:20
14:20 - 15:00
PAHO/WHO resolutions on dengue/DHF Jorge Arias/Mike Nathan
Presentation of DengueNet - WHO's Internet based Renu Dayal Drager
system for global surveillance of dengue/DHF
15:00 - 15:30 COFFEE
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  DengueNet hands-on session with the internet site            Gary Clark/
Discussion DengueNet system Renu Dayal Drager
Centre visit and individual meetings
VENUE:  Wednesday 10 July – Thursday 11 July 2002
Condado Plaza Hotel, San Juan Puerto Rico
Time Wednesday 10 July 2002     Presenter/Moderator
Session 3
8.30 – 9:15
Review of the 1994 &1996 WHO Meetings on Dengue Moderator: Francisco Pinheiro
Laboratories in the Americas
Presentation of recommendations, follow up and Gary Clark
pending issues
9:15 – 10:00 Summary presentation of day 1 discussions on  Ray Arthur
Denguenet implementation/ pilot testing
10:00 – 10:15 Break up into two working groups Chairman/Renu Dayal-Drager




Working groups on epidemiology and laboratory
Participants, moderators and rapporteurs Chairman/Renu Dayal Drager
Working group 1: Epidemiology      Moderator: José Rigau
Rapporteurs: João Siqueira & Enid Garcia
Working group 2: Laboratory  Moderators: Vance Vordham &
Rapporteurs: Delia Enria & Rosa Alba Salas Francisco Pinheiro
11:00-12.30 Working  groups
12:30-13:30 LUNCH
13:30-17:30 Working  groups (cont.)
18:00 Cocktail reception - bus from hotel




Reports of working groups in plenary session
Report of working group 1: Epidemiology João Siqueira




Discussion, concensus and recommendations Chairman/Ray Arthur
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Annex 2: List of participants
Meeting on Denguenet Implementation in the Americas
Follow up of 1996 Rio de Janeiro and 1994 Cincinnati Meetings of Dengue Laboratories
9 – 11 July 2002




Setor de Embaixadas Norte
Lote 19 70800-400 – Brasília









Tel/Fax: +91 224 8446
E-mail: pinheirofp@uol.com.br
Dr Joao Bosco Siqueira
Epidemiologist
Gerência Técnica de Dengue
Fundação Nacional de Saúde
Setor de Autarquias Sul lote 04
Bloco N sala 730
70 058-902 Brasília DF
Tel/Fax: +55 61 225 0350






CAREC (Caribbean Epidemiology Centre)
16-18 Jamaica Boulevard
Federation Park
Port of Spain, Trinidad, W.I.
Tel: +868 622 2152/4261
Fax: +868 622 1008/2792
Email: boissoel@carec.paho.org
Dr Rosa Alba Salas
Virologist, Laboratory Division
CAREC (Caribbean Epidemiology Centre)
16-18 Jamaica Blvd.
Federation Park
Port of Spain, Trinidad, W.I.
Tel: +1 868 622 2324




Lic.  Patricia Lissette Mira
Profesional en Laboratorio Clínico de la Sección de
  Dengue
Laboratorio de Referencia
Alameda Roosevelt Contiguo a Hospital
Rosales San Salvador
El Salvador
Tel/Fax: +503 221 5751
Email: labcentral.sv@hotmail.com
Dr Romeo Humberto Montoya
Colaborador Técnico de la Unidad de
Epidemiología
Ministerio de Salud Publica y Asistencia Social
Calle Ruben Dario #2021, El Salvador
Centro America
Tel: +503 221 1618/222 1816
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Ingénieur en Chef du Génie Sanitaire
Direction Interrégionale de la Sécurité sociale
  des Antilles et de la Guyane
CIRE Antilles Guyane
Centre Delgrès - BP 656
97263 Fort de France Cedex
Tel: +596 71 75 67
Fax: +596 63 85 98
Email: ablateau@outremer.com
Dr Pascal Chaud
Médecin Inspecteur de Santé Publique Direction
Interrégionale de la Sécurité sociale
  des Antilles et de la Guyane
CIRE Antilles-Guyane
Centre Delgrès - BP 656
97263 Fort de France Cedex
Tel: +596 71 75 67




Responsible de Diagnóstico Clínico de Dengue
Laboratorio Nacional de Salud
Km. 22, Carretera al Pacífico
Barcenas Villa Nueva
Tel: +502 630 6020




Responsible del Programa Nacional de Dengue
Unidad/Departamento:
  Programa Nacional de Dengue
Programa Nacional de Vectores
Finca la Verbena, zona 7
Tel: +502 472 0300
Fax: +502 472 0300
Email: ryomeridakno@yahoo.com 
       ryomeridakno@hotmail.com
HONDURAS
*Dr Dina Yanet Castro
MEXICO
Dr Luis Anaya Lopez
Subdireccion de vigilancia Epidemiologica
Direccion General de Epidemiologia
Francisco de P. Miranda 177, 6th floor
Mexico DF
Tel: +55 93 6621
Fax: +55 93 0713
Email:  lanaya@epi.org.mx
Dr Enid Eunice Argot Ramírez
Centro Nacional de Vigilancia Epidemiologica
INDRE, Prol. Carpio 470
Col. Sto. Tomás C.P. 11340
México D.F.
Tel: +53 41 14 32
Fax: +53 41 14 32
Email: enid-argott@yahoo.com
NICARAGUA
Dr Aida Mercedes Soto Bravo
Consultura
OPS/OMS/ Nicaragua
Complejo Nacional de Salud
Tel: +505 289 4200
Fax: +505 289 4999
Email: sotoa@nic.ops-oms.org
Dr Wendy Cecilya Idiáquez Mendoza
Vigilancia Epidemiológica de Dengue
Dirección General de Salud Ambiental y
  Epidemiología, Complejo Nacional de Salud,
“Dra. Concepción Palacios”, Apartado postal 107,
Managua, Nicaragua
Tel: +505 2897 997/289 4312
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NICARAGUA PUERTO RICO
Lic Leonel Pérez Escobar
Virología
Centro Nacional de Diagnóstico y Referencia
Complejo Nacional de Salud
Costado oeste colonia primero de mayo
Managua, Nicaragua
Tel: +289 77 23




Puerto Rico Department of Health
P.O. Box 70184
San Juan - PR 00936
Puerto Rico




Puerto Rico Department of Health
P.O. Box 70184
San Juan, PR 00936
Puerto Rico
Tel: +1 787 274 7606
Fax: +1 787 250 6547
Email: jrullan@salud.gov.pr
Dr Raul Castellanos
Puerto Rico Health Department representative
  to PAHO
Puerto Rico Department of Health
P.O. Box 70184
San Juan, PR 00936
Puerto Rico




Epidemiólogo de la Dirección de Vigilancia
  Epidemiológica y Análisis Estratégico
Ministerio de Salud y Desarrollo Social (MSDS)
Caracas
Venezuela
Tel: +39 0212 482 3330/0212 482 2139/02124




Jefe de División de enfermedades Transmisibles
Laboratorio de Dengue
División de Diagnóstico de enfermedades
  Transmisibles
Instituto Nacional de Higiene “Rafael Rangel”
Universidad Central de Venezuela
Caracas
Venezuela
Tel: +58 212 693 4476




Dr Duane J. Gubler
Director
Division of Vector-Borne Infectious Diseases Centers
  for Disease Control and Prevention
P.O. Box 2087, Foothills Campus
Mail stop P02
Fort Collins - CO 80522
USA
Tel: +970 221 6428




Uniformer Services University of
  Health Sciences
Department of Preventive Medicine
  and Biostatistics
5824 Edson Lane, Rockville
N. Bethesda - MD 20852, USA
Tel: +240 463 2930
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SOUTH-EAST ASIA (SEA) AND WESTERN PACIFIC (WPR)
INDONESIA THAILAND
Dr Rita Kusriastuti
Head of Sub-Directorate Arbovirus
Directorate General CDC & Environment
Ministry of Health
Jl. Percetakan Negara No. 29
Jakarta
Indonesia
Tel: +62 21 424 7608 ext. 153












Dr Nguyen Thi Kim Tien
Director
Institute Pasteur HCMC
167 Pasteur St., District 3
Ho Chi Minh City
Viet Nam
Tel: +84 8 820 3313
Fax: +84 8 823 1419
Email: Ktien@HCMC.NETNAM.VN
WHO COLLABORATING CENTRES  IN THE AMERICAS (WHO CC):
WHOCC – ARGENTINA *WHOCC – BRAZIL
Dr Delia A. Enria
Instituto Nacional de Enfermedades
  Virales Humanas, Monteagudo 2510
2700 Pergamino - Provincia de Buenos Aires
Argentina
Tel: +54 2477 433 044/429 71214
Fax: +54 2477 433045
Email: inevh@satlink.com
picco@satlink.com
Dr Pedro Fernando da Costa Vasconcelos
Instituto Evandro Chagas
c/o Fundação Nacional de Saúde
Av. Almirante Barroso 492, C.P. 621 66090-000
Belem, PA
Tel: +55 91 211 4409 or 226 5262
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WHOCC – BRAZIL WHOCC – CANADA




Av. Dr. Arnaldo 355
São Paulo – SP 01246-902,  Brasil
Tel: +55 11 3068 2904/3068 2903






1015 Arlington St., Room H4700
Winnipeg, Manitoba R3E 3R2
Canada
Tel: +1 204 789 2134
Fax: +1 204 789 2082
Email: harvey_artsob@hc-sc.gc.ca
*WHOCC-CUBA WHOCC-USA
Dr María G. Guzman
Instituto de Medicina Tropical Pedro Kouri Autopista (IPK)
Novia del Mediodia Km 6
Mariano 16
Havana – 11500,  Cuba
Tel: +53 7 204 910
Fax: +53 7 246 051
Email: gkouri@infomed.sld.cu
Dr Robert Shope
The University of Texas Medical Branch (UTMB)
Pathology  Department
301 University Boulevard
Galveston - TX 77555-0609,  USA
Tel: +409 747 2430





Global Alert and Response, Communicable Disease





Tel: +41 22 791 2658
Fax: +41 22 791 4198/4878
Email: arthurr@who.int
Dr Michael B. Nathan
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Annex 3:   Background documents
Participants received the following background documents at the meeting:
 2002 WHO Executive Board report on dengue prevention and control;
 2002 World Health Assembly Resolution on dengue;
 WHO dengue fact sheet;
 Dengue haemorrhagic fever, 2nd ed.;
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Annex 4: Abstracts of presentations of national programmes
PAHO Survey of National Dengue Programmes and Laboratories
Dr Jorge Arias
A comprehensive questionnaire was developed for dengue national programmes and
laboratories and a preliminary survey was conducted for participating countries and WHO
Collaborating Centres.  Preliminary results of the completed questionnaires are reported.
All laboratories surveyed have adequate equipment.
Dengue is of mandatory obligation in 8 of the countries, not obligatory in 3 and there was no
response from one.  This information includes the CC countries.
DHF is of mandatory notification in 7 of the countries, not obligatory in 4 and there was no
response from one.  This information includes the CC countries.
Dengue reporting frequency is variable depending on the country and the situation.  During
epidemics it is daily.
Dengue is notified by a wide array of methods; electronic, paper, mail, fax, telephone.
Table 1.- Number of questionnaires sent / received
Sent Received
Collaborating Centers (CCs) 8 8*
Countries 7 5**
Total 15 13
*includes CAREC ** one not included in results
Table 2.- Communication
W/ internet Home pg.
Collaborating Centers (CCs) 8 7
Countries 3 2**
Total 11 9
Table 3.- Human resources available
Central lab. Other labs.
Collaborating Centers (CCs) 2 to 21 --
Countries 8 to 26 2 to 124
Table 4.- Affiliation and financing
Affiliation Financing
Collaborating Centers (CCs) Public Health
University
Cent.  Gov., Local Gov.
PAHO, WHO, others
Countries Public Health Central Gov.
PAHO, WHO, USAID
Table 5.- Training
1999 - 2001 Financing
Collaborating Centers (CCs) >150 CCs, various
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Table 6.- Communication with PAHO
Yes / no Requires authorization
Yes / no
Collaborating Centers (CCs) 4 / 4 4 / 4
Countries 3 / 1 2 / 2
Table 7.- Want to participate in DengueNet?
Yes / no
Collaborating Centers (CCs) 6 / 1 (1 nr)
Countries 3 / 0 (1 nr)
(nr = no response)
Table 8.- Are reference laboratories?
Yes / no Level
Collaborating Centers (CCs) 8 / 0 World, regional, national
Countries 4 / 0 National, state
Number of laboratories in the countries vary from 1 to 33.
Table 9.- Number of samples processed for:
Surveillance Lab.  capacity Actual capacity
Collaborating Centers (CCs) 7 adequate,1 insufficient
6 adequate,
2 too many
5 as at present,
2 double actual,
1 no limit
Countries 4 adequate 3 adequate,2 too many
3 as at present,
1 double
Table 10.- Identification of virus
Number of isolates % success virus isolation
Collaborating Centers (CCs) 200 to 37,000 14.5 to 25.8%
(variable per year)
Countries 3,500 to 12,000 8.2 to 44%
(variable per year)
Table 11.- Antigens
Prepare their own Can supply
Collaborating Centers (CCs) 7 yes, 1 nr 6 yes, 1 no, 1 nr
Countries 3 yes, 1 nr 2 yes, 2 no
Table 12.- Quality control
Has internal QC Participates in external QC
Collaborating Centers (CCs) 6 yes, 1 no, 1 nr --
Countries 4 yes 4 yes
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The dengue surveillance system in Puerto Rico  http://www.salud.gov.pr/index.asp
José G.  Rigau-Pérez, MD, MPH, Chief, Epidemiology Section, CDC Dengue Branch
Dengue surveillance in Puerto Rico is a joint effort of the Puerto Rico Department of
Health (PRDH) and the US Centers for Disease Control and Prevention.  A reported case is
defined as any person whose illness is considered compatible with dengue by a health care
professional in Puerto Rico, and whose diagnostic sample is sent to the CDC Dengue Branch for
testing.  For DHF, we adhere strictly to the WHO/PAHO definition.  The routine laboratory
methods are virus isolation, IgM and IgG (ELISA) tests, and immunohistochemistry for antigen
detection in autopsy samples.  At least 75% of reported cases are dengue (that is, the predictive
value of a report is at least 75%).
The goals and objectives of the Puerto Rico dengue surveillance system are to provide
early and precise information on when and where transmission is occurring, the serotypes present,
and disease severity; and to predict transmission and guide implementation of clinical
and vector control measures (anticipatory or proactive surveillance).  This is a laboratory-based,
population-based surveillance system, with close coordination of epidemiology and laboratory
components.  Physicians, laboratories, and hospitals send diagnostic samples and Dengue Case
Investigation Forms (DCIF) from throughout the island.  Voluntary reports of hospitalized
suspected dengue cases are sent by the hospital Infection Control Nurses.  We also review all
death certificates from Puerto Rico that mention dengue.  There is no routine entomologic
surveillance, but the surveillance system is constantly evaluated.  Diagnostic results are provided
to the submitting source and to PRDH vector control staff, and epidemiologic analyses are
disseminated through weekly surveillance reports with a solid statistical basis (for determination
of deviations from expected trends).  Early signals for increase in dengue activity include a virus
isolation positivity rate greater than 9% in May (typically the month of lowest dengue incidence),
and significant increases in reports (compared to baseline average, even if few cases) from
municipalities or throughout the island.
Key attributes of the surveillance system include simplicity (submission of sample fulfils
the legal reporting requirement), acceptability (there is no charge for transport and testing, and test
results are returned to the submitting source), flexibility (during epidemics, alternate methods can
be adopted), high coverage (samples are received from all 78 cities, all age-groups and socio-
economic levels).  Severity markers have high specificity (>95%) but low sensitivity (passive
reporting identifies 7% of DHF cases).  Timeliness is constrained by the characteristics of disease
transmission and diagnostic methods, so that an average 17 days elapse
from transmission to report (mosquito bite to onset of disease - 7 days, onset to delivery of sample
- 10 days).  No exact budget data are available to define the monetary costs incurred by the CDC
and PRDH for dengue surveillance in Puerto Rico, but the system involves an estimated 25
persons (not full time; they have other responsibilities as well).
Dengue Fever in Brazil – past, present and perspectives  www.funasa.gov.br
Dr João Bosco Siqueira Jr., Centro Nacional de Epidemiologia
Brazil is located in South America and has a population around 174 million people.  The
country has 27 states distributed in 5 regions: North, Northeast, Southeast, Central-West and
South.  Together the Northeast and the Southeast regions represent 70% of the population.
Dengue was first detected in 1986 in Rio de Janeiro state, with the introduction of dengue
serotype 1.  Dengue 2 was also detected in Rio in 1990.  During the 90’s the number of
municipalities infested with Aedes aegypti had a major increase, especially after 1994.  This led to
an increase incidence of dengue in the second half of last decade.  Initially cases were only
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reported in the Northeast and Southeast regions.  After 1994 cases started to occur in the Central-
West and in the North regions as well, however the majority of the cases were still reported in the
NE and SE regions.  The highest incidence was observed in 1998 with over 530,000 cases.
Dengue 3 was detected in the state of Rio de Janeiro in December, 2000.  This new
serotype was responsible for Brazil’s largest epidemic in the first four months of 2002 which to
date has resulted in over 560,000 cases being reported (preliminary data).  The state of Rio the
Janeiro represented 53% of this total between January and March, 2002.  Epidemics were also
detected in the other regions except for the North which reported  60% fewer cases than the year
before.
The epidemic in Rio de Janeiro forced the Ministry of Health to adopt additional control
measures.  A task force was organized and was temporally transferred to Rio.  This consisted of 18
supervisors and a 1,000 dengue control field agents selected from other states.  The Armed Forces
also participated in this operation, sending 1,300 men to work in larvae source reduction along
with the task force.  Truck mounted and back pack ULV were used to reduce adult  mosquito
populations.  Medical assistance / access were improved with the training of health care workers,
increased staff availability and 24 hour outpatient clinics.
A dengue D-Day was also organized.  For this day FUNASA´s Board of Directors moved
to Rio de Janeiro.  A Community Mobilization Committee and an intense media campaign (radio,
TV, newspapers, posters, folders) were organized and coordinated with neighborhood
associations, including: churches, local media, other institutions.  Over 18 million pamphlets with
information on household dengue prevention were distributed.  A total of 30,536 civil servants and
714,445 volunteers participated in the activities.  A total of 5,291 tons of garbage was collected
and removed from strategic areas.  At least 3,210 non-occupied residences were visited.  The
number of reported cases started to reduce in the end of February and now only few cases are
being reported.
Eradication of Aedes aegypti cannot be achieved in a short term.  All efforts must be to
prevent disease instead of controlling outbreaks.  The National Program for Dengue Control for
the  prevention  and control of dengue will be presented to the minister in July 2002.  This
program strategy focuses on regional specificity (actions according to regional problems),
integration of control  activities (vector control, health education, community mobilization,
surveillance, water supply problems and adequate garbage handling), continuous prevention
actions and personnel training for surveillance, medical assistance and vector control activities.
The objectives are:
 To reduce dengue incidence dengue by 50% in 2003 and 25% for each following
year.
 To prevent dengue outbreaks and reduce the case fatality rate DHF to below 1%.
 To reduce the infestation indexes of Aedes aegypti to below 1%
A brief summary of the program components is listed below:
 Surveillance – improve actions by integrating cases and laboratory based
surveillance with vector control activities.
 Medical assistance – continuous training of health care works to handle DHF
 Vector control activities – training over 70,000 filed supervisors
 Integrated actions of health education and community participation
 Legislation – identifying and approving laws to deal with closed buildings
 Evaluation and follow up of the programme
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The National Program of Dengue Control will soon be available on FUNASA’s web page
www.funasa.gov.br.  Data on dengue cases for 2002 and past years is also available at this site.
Dengue Surveillance in CAREC Member Countries  http://www.carec.org
Dr  Eldonna Boisson, CAREC
The Caribbean Epidemiology Centre (CAREC) is a PAHO/WHO health monitoring and
disease prevention agency, that provides laboratory reference and epidemiology services to 21
member countries in the Caribbean.  These countries range in size from 21 to 4,411 square miles
and have a total population of 7.2 million people, ranging from 4,000 to 2.5 million people per
country.
CARISURV is a surveillance system for the collection, analysis, interpretation, reporting
and dissemination of Caribbean public health and is comprised of twelve components.  Three of
these components have a focus on dengue surveillance, namely, EPISUM (the communicable
disease database), LABIS (the laboratory information system) and PHLIS (the Public Health
Laboratory information System).
CAREC member countries use the following case definitions for dengue fever, dengue
haemorrhagic fever (DHF) and dengue shock syndrome (DSS):
Dengue fever
Probable case: A person with acute onset of fever and two or more of the following:
- Headache - Rash
- Retro-orbital pain - Haemorrhagic manifestations
- Myalgia - Supportive serology (e.g.  high single HAI titre)
- Arthralgia
Confirmed case
 Laboratory confirmed: A probable case with diagnostic laboratory findings
 Epidemiologically confirmed: A probable case occurring at the same location and
time as a laboratory confirmed case DHF
Probable case: A person with fever or recent history of fever and evidence of:
 Haemorrhagic tendancies
 Thrombocytopenia (100,000 mm3 or less)
 Plasma leakage
Confirmed case: Same as for dengue fever
DSS
Probable case: Evidence of circulatory failure manifested by all of the following:
 Rapid and weak pulse
 Narrow pulse pressure or hypotension for age
 Cold clammy skin and altered mental status
Confirmed case: Same as for dengue fever
Laboratory diagnosis of dengue is defined by one of the following:
 Detection of IgM antibodies to the dengue virus by capture ELISA
 Isolation and identification of dengue virus from acute serum
 Dengue virus in clinical material in  PCR
 Fourfold or greater rise in flavivirus antibody titres between acute and convalescent
phase serum specimens by the HI test
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The objectives of laboratory surveillance are to identify new serotypes, identify spread of
the epidemic into new areas and to monitor severe, complicated and fatal cases attributed to
dengue fever.  As such, during an epidemic, laboratory surveillance occurs on a limited number
of probable cases and all laboratory confirmations on new dengue types are reported
immediately.
The larger CAREC member countries have three reporting levels for communicable
diseases, in many of the smaller countries the functions of level 2 are split between levels 1
and 3.
The functions of Level 1 are to:
 Identify probable cases
 Complete case investigation forms
 Collect acute blood samples
 If necessary, report outbreaks to level 2
 Forward laboratory results to level 2
The functions of level 2 are to:
 Conduct epidemiological investigations of all cases reported by level 1
 Forward weekly reports to the national level
The functions of level 3 are to:
 Collate country reports
 Institute control measures if necessary
 Report summary data to CAREC
Surveillance of dengue vectors is done via:
 Measurement of container indices (House index, Breteau index, container index)
 Collection of eggs by ovitrap
 Collection of adults by backpack aspirator
Since 1991, there has been an upward trend of reported cases of dengue and DHF/DSS
from CAREC member countries.  The disease has also been seasonal, with greater numbers of
cases being reported in the rainy season.
Between 1977 and 1994 dengue viruses type 1, 2 and 4 have been circulating in the
Americas.  Dengue virus type 3 was first introduced into the Caribbean in 1997 and to date
almost all member countries have reported cases of DEN-3.
Information on Epidemiological Surveillance of Dengue in El Salvador (Summary)
http://www.mspas.gob.sv/vigilancia_epid2002.htm
Dr Romeo Humberto Montoya/Ministerio de Salud de El Salvador
Surveillance objectives
Maintain a surveillance system of national reportable diseases, with emphasis on quality
and timeliness, especially for dengue since this has become a public health problem in El
Salvador from the beginning of the 1970s. The objective is  to provide information for adequate
decision-making to our authorities at national, state and local levels.
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Data collection
There is a weekly epidemiological report for several diseases including dengue and DHF
that includes data on sex, age, facility, department or state.
There is also daily surveillance for dengue, which is compulsory during epidemics. Data
collected include: name, age, sex, address, department, municipality, date of start of symptoms,
date of sampling (IgM), symptoms, laboratory tests, contacts of patient.
Information flow
Begins when the patient comes into contact with the physician in the health centre or
hospital and is clinically suspected to have dengue, in accordance with the case definition
established by the national standard for dengue. The physician fills the sheet with case reporting
form and reports via fax to the higher level (Basic Comprehensive Health System - SIBASI). In
turn, SIBASI reports to the central level (National Unit of Epidemiology) where the information
is entered into a database (EpiInfo) for  analysis.
Actions against dengue are initiated from the first clinical suspicion without waiting for
the laboratory confirmation as this takes between 1 to 2 weeks.
Coordination between epidemiology and laboratory
We coordinate closely with the laboratory, not only for epidemiological surveillance of
dengue but for others diseases.   Joint projects include  the establishment of the network of viral
dengue surveillance in border areas and in the interior of the country.
Weaknesses and challenges
The principal weakness is  understaffing of the epidemiology unit and the shortage of
epidemiologists in the SIBASI. We are addressing this by training epidemiologists with the
support of the CDC.  At present 80 have been trained in basic epidemiology, 40 graduates in
epidemiology , and 6 are being trained in field epidemiology. The second group is being trained,
in order to strengthen the basic and intermediate levels.
Epidemiological dengue surveillance system in Mexico
http://busqueda.yupimsn.com/categorias/salud/enfermedades/infecciosas/dengue/
Dr Luis Anaya Lopez, Subdireccion de vigilancia Epidemiologica, Direccion General de
Epidemiologia, Ministerio de Salud
Surveillance Objective
Provide quality and timely information to support the health personnel and activities of
the National Program of Vector-borne Disease Prevention and Control.
Data Collection and information flow
Epidemiological surveillance is legally based on the 4th Constitutional Article, of the
general health law that is the basis of the Mexican Official Standards/Norms (NOM).  NOM 017
deals with epidemiological surveillance and another NOM for the prevention and control of
Dengue.
In Mexico the National Center of Epidemiological Surveillance oversees the General
Bureau of Epidemiology, the Institute of Epidemiological Reference (surveillance laboratory),
and the National Program of Disease Prevention and Control.  Within this scheme, the General
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Within the SINAVE is the Single Information System for Epidemiological Surveillance
(SUIVE), which generates morbidity information using three formats. The SUIVE 1 form
collects weekly data of over 90 diseases including  DENGUE. This is part of passive
surveillance. The SUIVE 2 form is the epidemiological case reporting form and is used to collect
data for the confirmed cases of DENGUE. The SUIVE 3 form collects data on outbreaks.
Mortality within the SINAVE is analysed within the framework of the Epidemiological
and Statistical System of Deaths (SEED). Death certificates are the source of information for this
system. Each death from DENGUE is investigated by the Jurisdictional Epidemiologist and can
be confirmed or rectified.
Another component of the SINAVE is hospital based surveillance, that is carried out
through the Hospital Network of Epidemiological Surveillance (RHOVE).  In this case
information on the management of cases hospitalized by DENGUE is produced.
The SINAVE has a pyramidal organization, the base is the local level, consisting of
medical units (around 16,000).  The next level is the jurisdictional formed by 256 health
jurisdictions throughout the country.  The following level is the state level consisting of 32 states,
and the top level is the national level.  The information flows from local to national level
following this structure
Weaknesses and challenges
The challenges are to improve both the quality and the timeliness of the information.
With regard to the timeliness, the principal problem is communication among the levels, and to
improve this an Internet system will be established at the end of this year.  With regard to the
improving quality of the information, training and other projects are being instituted  to improve
adequate filling of the forms and strengthening laboratory capacity.
Epidemiological Surveillance of Dengue Nicaragua  http://www.minsa.gob.ni/
Dr Wendy Cecilya Idiáquez Mendoza, Vigilancia Epidemiológica de Dengue, Dirección
General de Salud Ambiental y Epidemiología
Surveillance objectives
Obtain timely information in order to carry out the actions of disease prevention and
control. Information for the action.
Data collection
Information is obtained through the forms for compulsory notifiable disease (ENO) and
information for 1st and 2nd sample.
Information flow
This is originated by the attending physicians at the different levels of care, then
transmitted to municipalities, then to the departments (in Nicaragua these are called SILAIS local
systems of comprehensive health care), and from there to national level.
Analysis is carried out at the central and SILAIS levels. The SILIAS have autonomy to
carry out the prevention and control actions. The national level carries out technical assistance
and supervision.
The software SISNIVEN is used for epidemiological surveillance, including dengue,
allows data entry from the municipal level upwards.
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Starting in July, work is being done on the  decentralization of the diagnosis of dengue in
three regional laboratories.
The feedback of the information is provided through  the  weekly Epidemiological
Bulletin available in hard copy and online.
Coordination between epidemiology and laboratory







Automation of the laboratory information
Medical consumables
Consubables for vector control
Incorporation of data into software on a weekly basis not daily.
There are geographical remote localities with difficult access to health units. As dengue
diagnosis continues to be centralized in the CNDR, the SILAIS are struggling with limited
budgets to cope with  the costs of shipment of lab specimens. To improve this situation,  in mid
June,  we have initiated a process of decentralization of the serological diagnosis of dengue.
Strengths
Location of Epidemiology in the organizational chart of the Ministry of Health.
Level of organization of Epidemiological Surveillance.
Existence of a Software with alert applications.
Feedback of the Surveillance System.
Personnel trained in field activities.
Programmatic ínter coordination
Functional system that regularly reports the cases and outcomes.
Challenges
Strengthening of Epidemiological Surveillance with human and financial resources.
Improvement of the currently used surveillance software.
Strengthening of hospital monitoring
Epidemiological Surveillance of Dengue Venezuela
http://www.msds.gov.ve/msdsweb/Index.html
Dra Fatima Garrido Epidemiólogo de la Dirección de Vigilancia Epidemiológica y Análisis
Estratégico, Ministerio de Salud y Desarrollo Social (MSdS), Venezuela
Objective
To obtain a timely picture of the health situation in Venezuela to implement appropriate
strategies of intervention to maximize a positive impact.
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Data collection
Most cases of dengue are notified by the physicians from both private and public
healthcare facilities. Venezuela also has a 800 telephone number for the public to report
suspected cases of dengue which are then investigated by health authorities. The  DHF cases are
notified through case report forms that include: age, sex, hospital, state, symptoms, lab results,
date of notification, date of onset, date sample were taken.
Information flow
Suspected dengue cases are reported by the examining physician (ambulatory, hospitals,
private health care centers) to the district health authorities. At this level the malaria
Unit is alerted to take control actions including treatment of the cases, health promotion, and
monitoring the clinical course of  patients. The district epidemiologist reports notifications and
analysis to the regional level on a daily, weekly, monthly basis. The districts report to the
epidemiology central unit (MSDS).
Coordination between epidemiology and laboratory
The cooperation is very good. There is dengue laboratory diagnostic capability in all the
states. The reference laboratory (INH) is in Caracas.
Weakness and challenges
There is a general problem of understaffing in the epidemiology services including for
dengue. Communication with remote states and parishes is difficult (no fax).  Need to improve
diagnosis for DHF.
Annex 5:  Case definitions dengue/DHF
Epidemiological Bulletin, Vol. 21 No. 2, June 2000
Dengue: Rationale for surveillance
Dengue fever, including Dengue Hemorrhagic Fever (DHF) and Dengue Shock
Syndrome (DSS), is the most significant arthropod-borne viral disease worldwide. It occurs in
over 100 countries and territories and threatens the health of over 2,500 million people in tropical
and subtropical regions. Dengue fever is a severe disease with high epidemic potential. An
estimated 500,000 patients, 90% of them below the age of 15, are hospitalized with DHF/DSS
every year. The World Health Organization (WHO) aims to accelerate the final development of
an attenuated dengue vaccine.
Recommended case definition Dengue fever
Clinical description: An acute febrile illness of 2-7 days duration with 2 or more of the
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Laboratory criteria for diagnosis:
One or more of the following:
 Isolation of the dengue virus from serum, plasma, leukocytes, or autopsy samples,
 Demonstration of a fourfold or greater change in reciprocal IgG or IgM antibody
titers to one or more dengue virus antigens in paired serum samples,
 Demonstration of dengue virus antigen in autopsy tissue by immunohistochemistry
or immunofluorescence or in serum samples by EIA,
 Detection of viral genomic sequences in autopsy tissue, serum or CSF samples by
polymerase chain reaction (PCR).
Case classification
Suspected: A case compatible with the clinical description.
Probable: A case compatible with the clinical description with one or more of the following:
 Supportive serology (reciprocal hemagglutination-inhibition antibody titre greater
than 1280, comparable IgG EIA titre or positive IgM antibody test in late acute or
convalescent-phase serum specimen);
 Occurrence at same location and time as other confirmed cases of dengue fever.
Confirmed: A case compatible with the clinical description, laboratory-confirmed.
Criteria for Dengue Hemorrhagic Fever/Dengue Shock Syndrome:
Dengue Hemorrhagic Fever:
A probable or confirmed case of Dengue and Hemorrhagic tendencies evidenced by one or more
of the following:
Positive tourniquet test
Petechiae, ecchymoses or purpura
Bleeding: mucosa, gastrointestinal tract, injection sites or other
Haematemesis or melaena
and thrombocytopenia (100 000 cells or less per mm3)
and evidence of plasma leakage due to increased vascular permeability, manifested by one or
more of the following:
more than 20% rise in average hematocrit for age and sex
more than 20% drop in hematocrit following volume replacement treatment compared to
baseline signs of plasma leakage (pleural effusion, ascites, hypoproteinemia)
Dengue shock syndrome:
All the above criteria, plus evidence of circulatory failure manifested by rapid and weak
pulse, and narrow pulse pressure (less than 20 mm Hg) or hypotension for age, cold, clammy
skin and altered mental status.
Recommended types of surveillance
Areas where no dengue transmission has been detected but where Aedes aegypti occurs:
surveillance of suspected cases with investigation of clusters of suspected cases for dengue.
Countries where disease is endemic with seasonal variations in transmission, and areas
where epidemic dengue occurs: routine weekly/monthly reporting of aggregated data of
suspected, probable and confirmed cases from peripheral to intermediate and central levels.
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Recommended minimum data elements
Case-based data at the peripheral level
Case classification (suspected/probable/confirmed), serotype, DHF/DSS present (Yes/No)




Travel history during past 2 weeks
Aggregated data for reporting
Number of cases by age group
Number of confirmed (and serotype)
Number of DHF/DSS cases by age group
Number of hospitalizations and deaths
Principal use of data for decision-making
Target high risk areas for intervention.
Monitor changes in serotype and rate of DHF/DSS.
Monitor trends in endemic disease or re-emergence of disease.


For copies, please contact:




Fax (+41) 22 791 2845
Email: cdsdoc@who.int
